Cargando…
Epigenetic targets in B- and T-cell lymphomas: latest developments
Non-Hodgkin’s lymphomas (NHLs) comprise a diverse group of diseases, either of mature B-cell or of T-cell derivation, characterized by heterogeneous molecular features and clinical manifestations. While most of the patients are responsive to standard chemotherapy, immunotherapy, radiation and/or ste...
Autores principales: | Ribeiro, Marcelo Lima, Sánchez Vinces, Salvador, Mondragon, Laura, Roué, Gael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236259/ https://www.ncbi.nlm.nih.gov/pubmed/37273421 http://dx.doi.org/10.1177/20406207231173485 |
Ejemplares similares
-
RHOA Therapeutic Targeting in Hematological Cancers
por: Santos, Juliana Carvalho, et al.
Publicado: (2023) -
Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma
por: Ribeiro, Marcelo L., et al.
Publicado: (2019) -
Ikaros as a downstream mediator of BCR blockade therapy in B-cell non-Hodgkin lymphoma
por: Ribeiro, Marcelo Lima, et al.
Publicado: (2022) -
Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas
por: Profitós-Pelejà, Núria, et al.
Publicado: (2022) -
Immune-Checkpoint Inhibitors in B-Cell Lymphoma
por: Armengol, Marc, et al.
Publicado: (2021)